FDA grants priority review for Roche ’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris

Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of MabThera/Rituxan® (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news